Multiple choices for HIV therapy with integrase strand transfer inhibitors

被引：0
作者：
Francois Raffi
Mark A Wainberg
机构：
[1] University Hospital of Nantes,McGill University AIDS Centre, Lady Davis Institute
[2] EA 4271,undefined
[3] Jewish General Hospital,undefined
来源：
Retrovirology | / 9卷
关键词：
Raltegravir; Elvitegravir; Dolutegravir; Integrase strand transfer inhibitors;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Two integrases inhibitors, raltegravir and elvitegravir, have now been approved by regulatory agencies for use in the treatment of HIV-infected patients; and the approval of a third such drug, dolutegravir, is expected during 2013 on the basis of several phase 3 clinical trials. The advent of this new class of antiretroviral (ARV) medications represents a major advance in the management of HIV infection, and each of these three drugs can be expected to continue to be an important component of ARV combination regimens.
引用
收藏
相关论文
共 95 条
[1]  
Malet I(2012)The future of integrase inhibitors of HIV-1 Curr Opin Virol 2 580-587
[2]  
Calvez V(2011)Differential sensitivities of retroviruses to integrase strand transfer inhibitors J Virol 85 3677-3682
[3]  
Marcelin AG(2012)Resistance to HIV integrase inhibitors Curr Opin HIV AIDS 7 401-408
[4]  
Koh Y(2011)G140S/Q148R and N155H mutations render HIV-2 integrase resistant to raltegravir whereas Y143C does not Retrovirology 8 68-2448
[5]  
Matreyek KA(2012)Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks Lancet 379 2439-2438
[6]  
Engelman A(2012)Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial Lancet 379 2429-35
[7]  
Mesplede T(2012)Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority study Lancet Infect Dis 12 27-1335
[8]  
Quashie PK(2011)Low-frequency HIV-1 drug resistance mutations and risk of NNRTI-based antiretroviral treatment failure: a systematic review and pooled analysis JAMA 305 1327-806
[9]  
Wainberg MA(2009)Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial Lancet 374 796-3106
[10]  
Ni XJ(2012)Pharmacokinetics and pharmacodynamics of once-daily versus twice-daily raltegravir in treatment-naive HIV-infected patients Antimicrob Agents Chemother 56 3101-915
12345678910